

**ACCOUNT INFORMATION**

ACCOUNT NO. \_\_\_\_\_ TELEPHONE NO. \_\_\_\_\_

ACCOUNT NAME AND ADDRESS \_\_\_\_\_

REQUESTING PHYSICIAN (PLEASE PRINT) \_\_\_\_\_ PHYSICIAN/AUTHORIZED SIGNATURE \_\_\_\_\_

REQUESTING PHYSICIAN NPI \_\_\_\_\_ REFERRING PHYSICIAN \_\_\_\_\_

**PATIENT INFORMATION**

CHART NUMBER \_\_\_\_\_ PATIENT D.O.B. \_\_\_\_\_

PATIENT LAST NAME \_\_\_\_\_ FIRST NAME \_\_\_\_\_ M.I. \_\_\_\_\_

STREET ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP CODE \_\_\_\_\_

SEX M  F

RACE: \_\_\_\_\_ MRN / PATIENT ID# \_\_\_\_\_ PATIENT TELEPHONE NO. \_\_\_\_\_

**BILLING INFORMATION**

Diagnosis/Signs/Symptoms in ICD-CM format in effect at Date of Service (Highest Specificity Required) \_\_\_\_\_

REQUIRED ICD-CM CODE(S): \_\_\_\_\_

BILL:  PRACTICE/FACILITY  PATIENT  MEDICARE  MEDICAID  INSURANCE  REFERRAL # \_\_\_\_\_

POLICY/ID# \_\_\_\_\_ GROUP # \_\_\_\_\_ 2<sup>ND</sup> INS POLICY/ID# \_\_\_\_\_ GROUP # \_\_\_\_\_

INSURANCE CARRIER \_\_\_\_\_ INSURANCE CARRIER \_\_\_\_\_

CLAIM ADDRESS \_\_\_\_\_ CLAIM ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_ CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

PATIENT HOSPITAL STATUS  INPATIENT  OUTPATIENT  NON-PATIENT

INSURED'S NAME \_\_\_\_\_ INSURED'S DOB \_\_\_\_\_

PATIENT'S RELATIONSHIP TO INSURED:  SPOUSE  CHILD  OTHER

**CLINICAL DATA**


Collection Date: \_\_\_\_\_

Fixative:  Cytolyt® / 95% EtOH  Other: \_\_\_\_\_

RNARetain® Reflex Testing Vial included

Additional Clinical Data: \_\_\_\_\_

Mark site(s) collected for fine needle aspirate based on location on the thyroid illustration:



**CYTOLOGY SPECIMEN #1 (use separate thyroid FNA kit for each specimen)**

FNA Site: \_\_\_\_\_ Number of Slides: \_\_\_\_\_

FNA, reflex to ThyGenX®\* if FNA results are indeterminate

FNA, reflex to ThyGenX®\* if FNA results are indeterminate, reflex to ThyraMIR® if mutation is negative or not fully indicative of malignancy

(ThyGenX® includes markers for BRAF, HRAS, KRAS, NRAS, PAX8/PPARgamma, PIK3CA#, RET/PTC1, and RET/PTC3; ThyraMIR® includes miRNA markers@)

\*Molecular testing requires sample in RNARetain® vial

**CYTOLOGY SPECIMEN #2 (use separate thyroid FNA kit for each specimen)**

FNA Site: \_\_\_\_\_ Number of Slides: \_\_\_\_\_

FNA, reflex to ThyGenX®\* if FNA results are indeterminate

FNA, reflex to ThyGenX®\* if FNA results are indeterminate, reflex to ThyraMIR® if mutation is negative or not fully indicative of malignancy

(ThyGenX® includes markers for BRAF, HRAS, KRAS, NRAS, PAX8/PPARgamma, PIK3CA#, RET/PTC1, and RET/PTC3; ThyraMIR® includes miRNA markers@)

\*Molecular testing requires sample in RNARetain® vial

**CYTOLOGY SPECIMEN #3 (use separate thyroid FNA kit for each specimen)**

FNA Site: \_\_\_\_\_ Number of Slides: \_\_\_\_\_

FNA, reflex to ThyGenX®\* if FNA results are indeterminate

FNA, reflex to ThyGenX®\* if FNA results are indeterminate, reflex to ThyraMIR® if mutation is negative or not fully indicative of malignancy

(ThyGenX® includes markers for BRAF, HRAS, KRAS, NRAS, PAX8/PPARgamma, PIK3CA#, RET/PTC1, and RET/PTC3; ThyraMIR® includes miRNA markers@)

\*Molecular testing requires sample in RNARetain® vial

**CYTOLOGY SPECIMEN #4 (use separate thyroid FNA kit for each specimen)**

FNA Site: \_\_\_\_\_ Number of Slides: \_\_\_\_\_

FNA, reflex to ThyGenX®\* if FNA results are indeterminate

FNA, reflex to ThyGenX®\* if FNA results are indeterminate, reflex to ThyraMIR® if mutation is negative or not fully indicative of malignancy

(ThyGenX® includes markers for BRAF, HRAS, KRAS, NRAS, PAX8/PPARgamma, PIK3CA#, RET/PTC1, and RET/PTC3; ThyraMIR® includes miRNA markers@)

\*Molecular testing requires sample in RNARetain® vial

Molecular thyroid testing performed by Interpace Diagnostics, LLC, Pittsburgh, PA

**ADDITIONAL TESTS**

© 2017 Laboratory Corporation of America® Holdings  
 CT Lic. #: CL-0356  
 1193 REV. 11/01/2017

When ordering tests for which Medicare or Medicaid reimbursement will be sought, physicians should order only those tests that are medically necessary for the diagnosis or treatment of the patient.  
 WHITE COPY TO DIANON PINK COPY TO PHYSICIAN

Cytolyt® is a registered trademark of Cytyc Corporation.  
 RNARetain® is a registered trademark of Asuragen, Inc.  
 ThyGenX® and ThyraMIR® are registered service marks of Interpace Diagnostics, LLC.

Refer to Determining Necessity of ABN Completion on reverse.  
 Symbols Legend  
 @ = Subject to Medicare medical necessity guidelines  
 # = Medicare deems investigational. Medicare does not pay for services it deems investigational

**SPECIMEN LABEL INSTRUCTIONS:**

- 1.) Complete the requisition with all requested information.
  - 2.) Remove the required number of labels from the front of this sheet.
  - 3.) Place one (1) label on each specimen container (not on the lid).
- PLEASE DISPOSE OF UNUSED LABELS.**

Name: _____	Name: _____	Name: _____	Name: _____
Coll. Date: _____	Coll. Date: _____	Coll. Date: _____	Coll. Date: _____
Site: _____	Site: _____	Site: _____	Site: _____
Name: _____	Name: _____	Name: _____	Name: _____
Coll. Date: _____	Coll. Date: _____	Coll. Date: _____	Coll. Date: _____
Site: _____	Site: _____	Site: _____	Site: _____

8310020279 RR Donnelley ©2017. All rights reserved. — 0687

## Test Combination/Panel Policy

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the LabCorp request form. LabCorp encourages clients to contact their local LabCorp representative or LabCorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all LabCorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. LabCorp will process the specimen for a Microbiology test based on source.

### Determining Necessity of Advance Beneficiary Notice of Noncoverage (ABN) Completion\*

- 1. Diagnose.** Determine your patient's diagnosis.
- 2. Document.** Write the diagnosis code(s) on the front of the requisition.
- 3. Verify.** Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or [www.LabCorp.com/MedicareMedicalNecessity](http://www.LabCorp.com/MedicareMedicalNecessity).
- 4. Review.** If the diagnosis code for your patient does not meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

\*An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

### How to Complete an Advance Beneficiary Notice of Noncoverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, LabCorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

1. Be executed on the CMS approved ABN form (CMS-R-131).
2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card.
3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column.
4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN.
5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary.
6. Be signed and dated by the beneficiary or his/her representative prior to the service being rendered.

### Symbols used to designate Medicare medical review as of 10/01/2017

@ = Subject to Medicare medical necessity guidelines.

% = Subject to Medicare frequency guidelines.

# = Medicare deems investigational. Medicare does not pay for services it deems investigational.

#### ThyGenX®

CPT Code 81445

#### ThyraMIR®

CPT Code 0018U



Dianon Pathology is a brand of Dianon Systems, Inc., a wholly-owned subsidiary of Laboratory Corporation of America® Holdings.